NOS is a Portuguese media holding company whose main assets include a satellite, cable operator, and ISP, a mobile phone operator, a movie distributor and a virtual carrier of mobile phone services. Its services include cable television, cable internet and VOIP. NOS is the spun-off media arm of Portugal Telecom. NOS produces several premium channels for the TV platform, which include SportTV and TVCine. NOS Audiovisuais is also the home-video distributor of Walt Disney Pictures, Warner Bros., DreamWorks and Paramount Pictures releases in the Portuguese market, alongside of launching several independent and European titles. Wikipedia.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-08-2014 | Award Amount: 22.57M | Year: 2015
Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being the second most common cause of death after cardio-vascular diseases and the main cause of mortality among people aged 4564. Today, an estimated 9 million individuals in Europe live with cancer (Globocan 2008, http://globocan.iarc.fr/). Cancer became a chronic disease which contributed substantially to the growth of medical expenditures and constitutes a major socio-economic challenge for Europe as well as globally. A rapid and effective bidirectional transfer of relevant cancer research findings between bench and bedside would play a pivotal role in addressing top-priority needs at the EU level to reduce incidence and mortality of malignancies and to improve the quality of life of cancer patients. The proposed ERA-NET Cofund TRANSCAN-2, in continuity with the preceding and ongoing TRANSCAN ERA-NET, aims at linking translational cancer research funding programmes in 15 Member States, 3 Associated Countries, and a third country. By concentrating transnational resources, TRANSCAN-2 will provide a critical financial and scientific mass for tackling large-scale problems, relevant for improving translational cancer research globally. A co-funded joint transnational call (JTC) will be launched focusing on the topic Intratumour heterogeneity in resistance to therapy and recurrence followed by three additional JTCs that will be implemented in a frame of multinational translational cancer research programmes. In addition, strategies will be developed for the enlargement of the network, for improvement of coordination and for an efficient communication and dissemination of the results of the consortium as well as of the research projects funded through the JTCs. The monitoring of the projects funded through the JTCs and the critical assessment of the performance of TRANSCAN-2, based on key indicators, will be also realised.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-12-2015 | Award Amount: 23.81M | Year: 2015
Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. Enhanced coordination across national boundaries is needed to accelerate the efforts to tackle this grand challenge. Such synergies have been created among 19 countries in Europe and beyond through the EU JPI on Antimicrobial Resistance (JPIAMR). JPIAMR has developed a Strategic Research Agenda (SRA) which defines the strategic and scientific priorities benefiting from co-ordination and co-operation at the European level and mobilised national funds for two joint transnational calls (JTC) 2014 and 2015 based on this. In the ERA-NET Cofund JPI-EC-AMR, an additional 23 million of national funds will be combined with a highly incentivising EC top-up fund to support a new transnational research programme. The aim of this programme is to unravel the complex dynamics of selection and transmission of antimicrobial resistance (AMR) according to the One Health concept. A multidisciplinary approach is necessary to identify and characterise the determinants that contribute to the spread of resistance at genetic, bacterial, animal, human, societal, and environmental levels, in order to provide scientific knowledge to design and evaluate cost-effective strategies that can decrease transmission of AMR in society. JPI-EC-AMR will launch additional JTCs without EC co-funding under the framework of the SRA. and perform additional joint actions in close collaboration with JPIAMR actions. JPI-EC-AMR will provide a better, quantitative understanding of drug-resistant bacteria in animals, foods, and the environment and to what extent they contribute to the burden of antibiotic-resistant infections in humans. Research in this area is crucial in order to provide the robust scientific evidence needed to make informed decisions regarding interventions and policy measures in hospital, community, and agricultural settings.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: ISIB-13-2015 | Award Amount: 2.43M | Year: 2016
The main objectives of the 2nd Coordination and Support Action (CSA) of the Joint Programming Initiative Healthy Diet for a Healthy Life (JPI HDHL) are to support the further implementation of JPI HDHL and to create a sustainable collaboration of Member States (MS), the European Commission (EC) and related international organisations. Support facilitated by the 2nd CSA will ensure sufficient progress on alignment and also on the ethos of joint programming in the area of nutrition and health becoming embedded within Member States research and innovation policies and programmes. The 2nd CSA will focus specifically on these issues and will take into account foresight and evaluation activities as important aspects for the future of research in the scientific and policy areas covered within the JPI HDHL. Objectives of the 2nd CSA: 1. Alignment of national research programs on health and nutrition 2. Mature collaboration between the MS and focus on a sustainable support structure for the JPI. 3. Increase collaboration with important stakeholders. Industry, science and policy will be invited to take ownership of areas of the JPI which are under their responsibility. 4. Communication activities of the JPI will increase to make the JPI an even more important player in the area of Nutrition & Health. 5. Show the impact of joint programming on Nutrition & Health within the MS. The evaluation of the JPI will go beyond pure process indicators and will focus on effect and impact evaluation. 6. The collaboration within the JPI will move beyond Europe. In the first phase Canada and New Zealand have become partners, but the next five years will be used to broaden the scope of the JPI to new interested countries with a specific focus on Asia and the Americas.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-13-2015 | Award Amount: 19.10M | Year: 2015
Cardiovascular diseases (CVD) are the largest cause of death in the EU and account for around 2 million deaths per year. Overall, CVD are estimated to cause the economy of the EU costs of almost 196 billion Euros a year. Furthermore, they are one of the leading causes of long term sickness, chronic diseases and loss to the labour market. Therefore, CVD are a major health problem in Europe. Despite the overall burden of CVD on European citizens and national health systems, translational cardiovascular research is fragmented and mainly occurs at national levels. However, the present and future challenges in cardiovascular research can only be met by an effective cooperation at transnational level. Therefore, the proposed European Research Area Network on cardiovascular diseases (ERA-CVD) aims to coordinate national and regional programmes for translational research in the area CVD by implementing one Joint Transnational Call (JTC2016) with EU Co-funding followed by further non-co-funded JTC (2017-2019). Although this consortium will be newly established, a collaboration and alignment of national programmes and activities has already been achieved during the preparation of the ERA-Net Co-fund proposal. This process is supported by CardioScape an EU-funded survey of the European cardiovascular research landscape coordinated by the European Society of Cardiology (ESC). The current ERA-CVD proposal will extend and strengthen the transnational cooperation of the current 23 ministries/institutions/foundations from 18 European, associated and third countries. Furthermore, ERA-CVD plans to cooperate with the ESC and the European Heart Network (EHN). Moreover, the collaboration with European Research Infrastructures, e.g. the ESFRI-initiatives is intended in order to set up an efficient European framework for innovative transnational research on CVD. Also the extension of the consortium and international collaborations are intended.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SC1-HCO-04-2016 | Award Amount: 2.23M | Year: 2017
EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR members research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SC1-HCO-06-2016 | Award Amount: 2.04M | Year: 2016
In order to strengthen the sustainability and resilience of health services and systems a unique consortium of governmental and funding organizations plus research institutes, has expressed the ambition to systematically learn from the organisation of care in other settings. Overall objective of TO-REACH is to provide groundwork for an ERA-NET that will contribute to the resilience, effectiveness, equity, accessibility and comprehensiveness of health services and systems. We will do so along two work streams: A) We will develop a research program on cross-border learning from good (or even innovative) models of care and the conditions needed to transfer them to other settings for implementation. It could refer to anywhere in the care chain depending on the priorities as identified in a Strategic Research Agenda (SRA) within this project. Conceptual, methodological and empirical advancement will be achieved through 4 meta-questions that will instruct research under the ERA-NET, linking to what counts as good models of care, what are the conditions required for transferability, what are the conditions for up-scaling, and how do they contribute to the performance of health care organisations and systems. B) We will build a platform for funding organizations that allows for collaboration and coordination in the project and projected ERA-NET. This will synchronize priorities and activities, hence improving the quality and applicability of research with a focus on the topic areas as described under A. TO-REACH will pursue five specific objectives: Mapping health system challenges and priorities by synthesizing different materials and stakeholder inputs; Developing a framework and providing a knowledge synthesis on the above-mentioned meta-questions; Establishing sustainable cooperation of research funding bodies and links with other initiatives; Developing a SRA through agenda setting at European and Member State level; Disseminating the results of TO-REACH.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: ISIB-12f-2015 | Award Amount: 15.59M | Year: 2016
ERA-HDHL is a proposal of ERA-NET Cofund in the field of nutrition and health to support the Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL). Nowadays, there is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The 24 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Between 2012 and 2015, JPI HDHL had implemented 7 JFAs with 40 M funds from national funding. The JPI HDHL is now set for further enhancement in tight coordination with the EC through the ERA-NET Cofund instrument. ERA-HDHL will provide a robust platform for implementing joint funding actions (JFAs) that address the needs identified in the JPI HDHL strategic research agenda and strengthen the research funding activities of JPI HDHL. An EC cofunded call on the identification and validation of biomarkers in nutrition and health will be implemented. For this foreseen action, the member countries of the JPI HDHL have doubled their financial commitment comparing to previous JFA implemented on a similar topic. Moreover, ERA-HDHL will launch at least 3 additional JFAs in line to fulfil the JPI HDHL objectives.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-09-2014 | Award Amount: 14.78M | Year: 2015
Systems medicine is a new approach which integrates biological and medical data with mathematical and computational modelling in order to understand the underlying mechanisms of disease and to develop new strategies for individualised diagnosis, treatment and prevention. Systems medicine can fill the gap between experimental data produced by modern technologies and medical knowledge. Through the implementation of systems biology approaches in both clinical research and medical practice systems medicine will provide a new tool to clinicians that will change the capabilities of the clinician to diagnose and treat patients faster, better and more effectively a tool, which has the potential to become a generic prerequisite for any personalized or P4 medicine approach. The central idea of ERACoSysMed is to implement systems biology approaches in medical concepts, research and practice by structuring, coordinating and integrating national efforts and investments during its project duration of five years. To achive this main goal the specific objectives of ERACoSysMed are: 1) Strengthen the systems medicine community both across national borders as well as across specific research areas 2) Establish a network of funding bodies to sustainably implement systems medicine across Europe 3) Launch joint trans-national research calls with the aim to push forward the desired paradigm shift towards P4 medicine 4) Provide a platform for the implementation of the actions recommended by the CASyM road map For this aim Joint transnational calls (JTCs) for research proposals will be implemented. As a first step a co-funded JTC call will be launched with the aim to select transnational research projects in a competitive approach that shall demonstrate the social and economic benefit of the systems medicine approach. The consortium intends to implement further JTCs and other networking activities in order to keep alive the momentum which will be created by the co-funded JTC.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-07-2014 | Award Amount: 30.95M | Year: 2015
Over 12 million people in Europe suffer from neurodegenerative diseases (ND), yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 28 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative action with 75 million of additional national funds being successfully mobilized between 2011 and 2014 to support transnational research programs. The JPND Research Strategy is now ripe for further enhancement in tight coordination with the EC through an ERA-Net Cofund instrument JPco-fuND with an unprecedented commitment of 30 million of national funds associated to a highly incentivizing EC top-up fund. Among the most burning questions, three priority topics have emerged through a consultative process between researchers and JPND members in order to unlock several major issues within ND research: the identification of genetic, epigenetic and environmental risk and protective factors, the development and maintenance of longitudinal cohorts, the creation of advanced experimental models. These are key questions of equal priority to increase understanding of ND mechanisms that will be addressed through a common joint transnational call allowing a significant acceleration of the execution of the JPND research strategy. Moreover, to expand the impact of JPco-fuND, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: SFS-19-2016-2017 | Award Amount: 10.60M | Year: 2016
HDHL-INTIMIC (INtesTInal MICrobiomics) is a proposal for an ERA-NET Cofund in the field of food, nutrition and health to support the Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL). There is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The intestine and in particular the intestinal microbiota have an influence on metabolic processes, thereby contributing to the development of lifestyle-related diseases. The 26 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Since 2012, JPI HDHL has implemented seven Joint Funding Actions (JFAs) with around 45 M national funding. In addition, the first ERA-NET Cofund under the umbrella of JPI HDHL, ERA-HDHL, has recently started, implementing an EC cofunded call on Biomarkers on Nutrition and Health with a committed budget of around 12 M. Building on these achievements, HDHL-INTIMIC will now further enhance the collaboration between JPI member countries and between the JPI and the EC by providing a platform for implementing further JFAs that address the needs identified in the JPI HDHL Strategic Research Agenda. In particular, a transnational Knowledge Platform on the interrelation of diet, intestinal microbiomics and health will be implemented via an EC cofunded call and an additional JFA. For this, the JPI HDHL members countries have increased their financial commitments comparing to a previous JFA on a similar topic, including also new partners in these activities. Moreover, HDHL-INTIMIC will launch 1-2 other additional JFAs in line to fulfil JPI HDHL objectives.